問卷

TPIDB > Search Result > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Surgery

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

Division of General Internal Medicine

更新時間:2023-09-19

吳尚殷Wu, Shang-Yin
  • Principal Investigator
  • Clinical Trial Experience (year) -23 years -4 個月
  • wusy.tw@gmail.com

篩選

List

421Cases

2022-02-28 - 2026-12-10

Phase I/II

Active
An Open Label, First-in-human Study of BAY 2927088 in Participants With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring an EGFR and/or HER2 Mutation
  • Condition/Disease

    Advanced Non-small Cell Lung Cancer、EGFR Mutation、HER2 Mutation

  • Test Drug

    BAY 2927088

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting2Sites

Terminated3Sites

2023-11-01 - 2025-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting3Sites

2015-09-15 - 2019-09-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated11Sites

2020-08-01 - 2024-11-29

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-08-01 - 2032-03-02

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-10-01 - 2028-12-31

Active
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2023-04-01 - 2027-08-31

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting5Sites

Recruiting2Sites

2015-01-01 - 2024-11-26

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2023-09-30 - 2026-06-30

Phase I

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2017-06-08 - 2019-12-31

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites